HIV Seronegativity Clinical Trial
Official title:
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP in Uninfected Adult Volunteers
This study will test the safety of an experimental vaccine against HIV and examine whether it
induces an immune response to HIV. A vaccine is a substance given to try to create resistance
or immunity to a disease or infection. The vaccine in this study is made from DNA (genetic
material) of four HIV proteins called 'gag', 'pol', 'Nef', and 'Env'. Injected into a human,
the viral DNA instructs the body to make small amounts of some HIV proteins. This study will
see if the body then creates an immune response to these proteins. Study participants cannot
catch HIV or AIDS from the DNA vaccine or any proteins made from it.
Healthy normal volunteers between 18 and 40 years of age may be eligible for this study.
Candidates will be screened with a medical history, physical examination and blood and urine
tests. Women will also have a pregnancy test. Women enrolled in the study must either be
infertile (e.g., due to menopause or hysterectomy) or must agree either to abstain from
heterosexual sex or to practice birth control for at least 21 days before beginning the study
and throughout its duration.
Participants will be randomly assigned to receive either the experimental vaccine or a
placebo (a salt solution that does not contain any active substance) and will be divided into
three groups, based on their entry into the study. Of the first seven people enrolled (Group
1), five will receive a 2-mg dose of vaccine and two will receive placebo. If the vaccine is
safe at this dose, then in Group 2, five people will receive a 4-mg dose of vaccine and two
will receive placebo. If this dose is safe, then in Group 3, thirty people will receive an
8-mg dose of vaccine and six will receive placebo.
All participants will receive three injections in an upper arm muscle-one injection a month
for three months-with a needle-less device called a Biojector 2000® (Registered Trademark).
At the time of each injection, participants will be observed for at least 1 hour after
immunization. At home, they will record their temperature and any symptoms they may
experience, including any effects at the injection site, for at least 7 days, or as long as
the symptoms remain. If symptoms occur, participants will report them immediately to the
clinic staff and, if necessary, come to the clinic for an examination.
Participants will have about 10 clinic visits during the study. Most visits will last about 2
hours; those on vaccination days will last about 4 hours. ...
This is a Phase I, randomized, controlled, double-blinded, dose-escalation study to examine tolerability, dose, and immune response of an HIV DNA plasmid vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to HIV. The primary objective is to evaluate the safety and tolerability in humans of VRC-HIVDNA009-00-VP and secondary objectives are to evaluate the immunogenicity of the vaccine and social impact of participating in an HIV-1 vaccine trial. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00065741 -
Botanical/Drug Interactions in HIV: Glucuronidation
|
Phase 1 | |
Completed |
NCT00056953 -
Peer Mentors for Adolescents in HIV Affected Families
|
Phase 2 | |
Completed |
NCT03995862 -
Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region
|
||
Completed |
NCT00006327 -
Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
|
Phase 3 | |
Completed |
NCT03086200 -
Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals
|
N/A | |
Completed |
NCT00076817 -
Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
|
Phase 1 | |
Completed |
NCT03191474 -
Linkage of Transgender Individuals to PrEP
|
N/A | |
Completed |
NCT00121121 -
Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers
|
Phase 1 | |
Completed |
NCT00009685 -
HIV-1 Vaccine Test in Uninfected Adult Volunteers
|
Phase 1 | |
Completed |
NCT00031304 -
Screening Protocol for HIV Vaccine Studies
|
||
Completed |
NCT00055237 -
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
|
Phase 2 | |
Completed |
NCT02125773 -
Pre-exposure Prophylaxis Accessibility Research and Evaluation 2
|
N/A | |
Terminated |
NCT00789789 -
Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
|
N/A | |
Completed |
NCT01761643 -
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
|
Phase 4 | |
Completed |
NCT01418235 -
Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT00028119 -
HIV Incidence and Participation Retention in Pune, India
|
||
Completed |
NCT00076232 -
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
|
Phase 3 | |
Completed |
NCT00004579 -
A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
|
Phase 1 | |
Active, not recruiting |
NCT00013572 -
HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
|
Phase 1 | |
Completed |
NCT00053612 -
Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
|
Phase 2 |